Equities analysts forecast that argenx SE – (NASDAQ:ARGX) will announce $25.00 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for argenx’s earnings. The lowest sales estimate is $10.17 million and the highest is $42.56 million. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that argenx will report full year sales of $79.91 million for the current fiscal year, with estimates ranging from $57.68 million to $114.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $53.07 million, with estimates ranging from $28.03 million to $92.82 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover argenx.
A number of research analysts have recently issued reports on ARGX shares. Zacks Investment Research downgraded shares of argenx from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a research report on Monday, February 4th. Piper Jaffray Companies lifted their price objective on shares of argenx from $161.00 to $182.00 and gave the stock an “overweight” rating in a research report on Thursday. Wedbush lifted their price objective on shares of argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Finally, Guggenheim started coverage on shares of argenx in a research report on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $147.55.
Several institutional investors have recently modified their holdings of the company. We Are One Seven LLC purchased a new stake in argenx during the 4th quarter worth approximately $27,000. Partner Investment Management L.P. purchased a new stake in argenx during the 4th quarter worth approximately $110,000. Marshall Wace LLP purchased a new stake in argenx during the 1st quarter worth approximately $121,000. SG Americas Securities LLC purchased a new stake in argenx during the 1st quarter worth approximately $134,000. Finally, Wells Fargo & Company MN purchased a new stake in argenx during the 1st quarter worth approximately $155,000. 65.68% of the stock is currently owned by hedge funds and other institutional investors.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Diluted Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.